Titan Spine raises Series B funding

Mequon medical device manufacturer adds $178,000

Mequon-based medical device manufacturer Titan Spine LLC has raised $178,043 from nine investors in a Series B round, according to a Dec. 30 filing with the SEC.

The interior of Titan Spine's manufacturing plant in Brown Deer.

The interior of Titan Spine’s manufacturing plant in Brown Deer.

The first sale in the offering was on Aug. 1.

Peter Ullrich, Jr., chief executive officer, could not be reached for comment about this raise.

Titan Spine previously raised $202,262 in October. In June, the company raised $7.5 million from Texas private equity firm Southlake Equity Group, which now has a minority ownership stake.

Titan, founded in 2006, makes a line of titanium interbody spinal implants equipped with a special grooved surface that encourages bone growth. The products are developed at its Mequon headquarters and manufactured in Brown Deer. The company, which has 72 employees, planned to use the other 2016 investments to support its rapid growth and commercialize its new nanoLOCK surface interbody device. Part of that process involves doubling its sales force.

Related Stories

Mequon-based medical device manufacturer Titan Spine LLC has raised $178,043 from nine investors in a Series B round, according to a Dec. 30 filing with the SEC.

The interior of Titan Spine's manufacturing plant in Brown Deer.

The interior of Titan Spine’s manufacturing plant in Brown Deer.

The first sale in the offering was on Aug. 1.

Peter Ullrich, Jr., chief executive officer, could not be reached for comment about this raise.

Titan Spine previously raised $202,262 in October. In June, the company raised $7.5 million from Texas private equity firm Southlake Equity Group, which now has a minority ownership stake.

Titan, founded in 2006, makes a line of titanium interbody spinal implants equipped with a special grooved surface that encourages bone growth. The products are developed at its Mequon headquarters and manufactured in Brown Deer. The company, which has 72 employees, planned to use the other 2016 investments to support its rapid growth and commercialize its new nanoLOCK surface interbody device. Part of that process involves doubling its sales force.

Related Stories

Comments are closed.